Alla studier
Aktiv men inte rekryterandeFAS2INTERVENTIONELL

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

This research study is investigating a new medication called Sonrotoclax for adults living with Waldenström Macroglobulinemia (WM), a type of blood cancer. The study will look at how safe and effective Sonrotoclax is when given on its own to patients whose previous treatments haven't worked well or whose cancer has returned. It will also be tested in combination with another drug, Zanubrutinib, for those who haven't received any treatment for their WM yet. The main goals are to see if the treatment can reduce the signs and symptoms of WM, or even make the cancer disappear, and to understand any side effects people might experience. Sonrotoclax works by targeting a protein called BCL2, which is often found in high levels in people with WM.

Överblick

Status
Aktiv men inte rekryterande
Fas
FAS2
Sponsor
BeOne Medicines
Inskrivningsmål
114
Starta
23 okt 2023
Beräknad slutförande
01 aug 2028

Vad handlar denna studie om?

This study is a research project designed to help us understand more about a new treatment for Waldenström Macroglobulinemia (WM). WM is a rare type of cancer that affects certain white blood cells. The new drug being studied is called Sonrotoclax. Researchers want to see if Sonrotoclax can help improve the health of people with WM.

The study will explore two main areas. Firstly, it will look at Sonrotoclax by itself in people who have already had treatment for their WM, but it hasn't worked as hoped, or their cancer has come back. Secondly, it will combine Sonrotoclax with another existing drug, Zanubrutinib, for people who are newly diagnosed with WM and haven't started any treatment yet. The main things the study will measure are whether the cancer shrinks or disappears, and what kind of side effects, if any, people experience.

Sonrotoclax works by targeting a specific protein called BCL2, which plays a role in how cancer cells survive. In many cancers, including WM, this protein can be overactive. By blocking BCL2, scientists hope to stop the cancer cells from growing and encourage them to die. This worldwide study plans to involve about 105 adult participants and will last for approximately five years. You might see the study sponsored by BeiGene or BeOne Medicines, as the company recently changed its name.

Viktiga punkter

  • This study evaluates a new drug, Sonrotoclax, for Waldenström Macroglobulinemia (WM).
  • It's being tested alone for previously treated WM and with Zanubrutinib for untreated WM.
  • Sonrotoclax targets a protein involved in cancer cell survival.
  • The study aims to understand the treatment's safety and effectiveness.
  • Participation involves taking daily pills and regular check-ups over several years.
  • It's a 'Phase 2' study, meaning it's exploring safety and early signs of effectiveness.

Vem kan vara berättigad?

To be considered for this study, you would need to have a confirmed diagnosis of Waldenström Macroglobulinemia (WM). Your medical team would also need to confirm that your WM meets certain guidelines for requiring treatment.

For some parts of the study, you would need to have WM that has either come back after treatment, or hasn't responded well to previous treatments. For another part of the study, it's important that you haven't received any prior treatment for your WM, apart from a procedure called plasmapheresis if you needed it.

There are also some things that would prevent you from taking part. For example, if your WM has spread to your brain or spinal cord, or if your WM has changed into a more aggressive form of lymphoma. You also wouldn't be able to participate if you've had another type of cancer within the last two years, or have an uncontrolled infection.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. I have a confirmed diagnosis of Waldenström Macroglobulinemia (WM).
  2. My WM requires treatment according to my doctor.
  3. I am an adult aged 18 or older.
  4. My WM is either relapsed/refractory OR I have not received previous treatment for WM.
  5. My WM has not spread to my brain or spinal cord.
  6. I do not have an uncontrolled infection at the moment.
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you will receive the study medication, Sonrotoclax, as a pill that you take by mouth. The overall study will involve regular visits and assessments with the study team to monitor your health, how you're responding to the treatment, and any side effects you might experience. These assessments typically include blood tests, physical examinations, and possibly scans or other tests to check on your WM. The total time commitment for individual participants in the study could be up to approximately five years, including treatment and follow-up.

Potentiella risker och fördelar

Participating in a clinical trial offers the potential benefit of accessing new treatments before they are widely available. While Sonrotoclax is being carefully studied, there's no guarantee it will work for everyone, and like all medications, it may have side effects. Potential risks will be thoroughly explained to you, including common and serious side effects observed so far. It's important to remember that your participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without affecting your standard care.

Platser (72)

  • City of Hope Nationella Medicinska Centrum
    Verifierat postnummer
    Duarte, USA
  • Colorado Blodcancerinstitut
    Verifierat postnummer
    Denver, USA
  • Medstar Georgetown University Hospital
    Verifierat postnummer
    Washington D.C., USA
  • Universitetet i Miami
    Verifierat postnummer
    Miami, USA
  • Northwestern Medicine Cancer Center
    Verifierat postnummer
    Warrenville, United States
  • Mission Cancer and Blood
    Verifierat postnummer
    Waukee, United States
  • University of Maryland Greenebaum Comprehensive Cancer Center
    Verifierat postnummer
    Baltimore, USA
  • Dana Farber Cancer Institute
    Verifierat postnummer
    Boston, USA
  • Mayo Clinic Rochester
    Verifierat postnummer
    Rochester, USA
  • Hattiesburg Hematology and Oncology Clinic
    Verifierat postnummer
    Hattiesburg, United States
  • Memorial Sloan Kettering Cancer Center Mskcc
    Verifierat postnummer
    New York, USA
  • Atrium Health Levine Cancer Institute (Lci)
    Verifierat postnummer
    Charlotte, USA

Vanliga frågor

What is Waldenström Macroglobulinemia?

It's a rare type of slow-growing blood cancer that affects certain white blood cells called lymphocytes, leading to too many abnormal cells in the bone marrow.

What does 'Relapsed/Refractory' mean?

Relapsed means your cancer came back after treatment. Refractory means your cancer didn't respond well to treatment, or it got worse while you were on treatment.

How does Sonrotoclax work?

Sonrotoclax targets a protein called BCL2, which helps cancer cells survive. By blocking this protein, the drug aims to stop cancer cell growth and encourage them to die.

Is Sonrotoclax available to everyone?

No, Sonrotoclax is an investigational drug, meaning it's still being studied in clinical trials and is not yet approved or available for general use.

What happens after the study ends?

After the study, the researchers will analyse all the information gathered. If the treatment is found to be safe and effective, it may eventually become a standard treatment option for WM, usually after further studies and approval from health authorities.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.